Drug Profile
Research programme: antibody-based anti-infectives - InhibRx
Alternative Names: INBRX-111; JET-MABLatest Information Update: 24 Aug 2022
Price :
$50
*
At a glance
- Originator Inhibrx
- Class Antibacterials; Antibodies; Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants; Surface antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 24 Aug 2022 Discontinued - Preclinical for Bacterial infections in USA (Parenteral)
- 24 Aug 2022 Discontinued - Preclinical for Viral infections in USA (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)